In a sporadic CRC model, targeting IL-23R in Treg cells increased IL-17 production by CD4+ T cells and increased the frequency of pro-inflammatory macrophages that was associated with decreased tumor volume and improved survival. This evidence concerns the gene CD4 and colorectal carcinoma.